“The Applicant evaluated the safety of adagrasib in GLP-compliant 28-day and 13-week repeat-dose toxicology studies in Sprague-Dawley rats and Beagle dogs, using the intended oral route of administration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Pivotal GLP studies
GLP 28-day and 13-week oral studies in Sprague-Dawley rats and Beagle dogs
“The Applicant evaluated the safety of adagrasib in GLP-compliant 28-day and 13-week repeat-dose toxicology studies in Sprague-Dawley rats and Beagle dogs, using the intended oral route of administration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Route in tox
Oral
“The Applicant evaluated the safety of adagrasib in GLP-compliant 28-day and 13-week repeat-dose toxicology studies in Sprague-Dawley rats and Beagle dogs, using the intended oral route of administration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗